Literature DB >> 1555289

Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization.

L Carlsson1, C Abrahamsson, L Drews, G Duker.   

Abstract

BACKGROUND: Earlier observations have indicated that repolarization-delaying agents may, under certain circumstances, have the propensity to induce polymorphous ventricular tachyarrhythmias (PVTs) (i.e., torsade de pointes). We have studied whether the potassium channel opener pinacidil and two of its pyridylcyanoguanidine analogues (P1075 and P1188) have any antiarrhythmic effects on clofilium-induced PVTs and triggered responses in rabbits in vivo and in vitro. METHODS AND
RESULTS: Anesthetized rabbits were pretreated with propranolol (2 mumol/kg i.v.) and subsequently given a concomitant intravenous infusion of clofilium (63 nmol/kg/min for maximally 15 minutes) and the alpha 1-agonist methoxamine (70 nmol/kg/min). In vehicle-pretreated rabbits (n = 19), clofilium invariably induced PVTs, which closely resembled torsade de pointes and were preceded by a marked prolongation of the QTU interval (27 +/- 2.4%, p less than 0.001). In a separate group of seven rabbits in which monophasic action potentials were recorded from the left ventricular endocardium, the tachyarrhythmia was preceded by deflections consistent with early afterdepolarizations (EADs) of the plateau repolarization phase of the monophasic action potentials. Intravenous administration of the pyridylcyanoguanidines in doses reducing mean arterial blood pressure by 25 or 50 mm Hg, respectively, was associated with a dose-dependent attenuation in the occurrence of clofilium-induced PVTs. In the pinacidil-pretreated rabbits (0.41 mumol/kg or 1.86 mumol/kg i.v.), the occurrence of PVTs was reduced from seven of seven rabbits to five of six and to three of seven rabbits (p = 0.035 versus vehicle-pretreated controls), respectively. In rabbits pretreated with the low dose of P1075 (0.01 mumol/kg i.v.), PVT occurrence was reduced from six of six rabbits to two of six rabbits (p = 0.030), whereas in six rabbits given the high dose of P1075 (0.13 mumol/kg), no PVTs appeared (p = 0.001). When the sulfonylurea glibenclamide (10 mumol/kg i.v.) was administered to rabbits before P1075 (0.13 mumol/kg) was infused, clofilium induced PVTs in five of six rabbits (not significantly different from the incidence in the vehicle-pretreated rabbits). Pretreatment with P1188 (4.36 mumol/kg or 11.88 mumol/kg i.v.) caused a reduction in the occurrence of PVT from six of six rabbits to five of six and to none of six rabbits (p = 0.001), respectively. In the six animals pretreated with the high dose of P1188 in which no clofilium-induced arrhythmias were elicited, glibenclamide (20 mumol/kg i.v.) was injected after the entire dose of clofilium had been administered. In these rabbits, premature ventricular systoles and PVTs appeared within a few minutes in five and four of the animals, respectively. In contrast to the pyridylcyanoguanidines, diltiazem pretreatment (0.9 mumol/kg i.v., decreasing arterial pressure by 50 mm Hg) did not attenuate PVT occurrence (five of six rabbits). Acute administration of P1075 (0.13 mumol/kg) during recurrent attacks of PVTs abruptly regularized the rhythm in 12 of 13 animals and diminished EADs observed in monophasic action potentials recorded from the left ventricular endocardium. In in vitro experiments, action potentials were simultaneously recorded from rabbit Purkinje fibers and ventricular muscle cells. Clofilium markedly prolonged action potential duration in Purkinje fibers but not in ventricular muscle cells, and eventually, bradycardia-dependent EADs and triggered activity were elicited. P1075 completely abolished EADs and triggered activity in all (six of six) experiments. Glibenclamide antagonized the suppressive effect of P1075; hence, EADs and triggered responses reappeared and resembled those present before P1075.
CONCLUSIONS: These results suggest that ATP-sensitive potassium channel activat
BACKGROUND: Earlier observations have indicated that repolarization-delaying agents may, under certain circumstances, have the propensity to induce polymorp

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1555289     DOI: 10.1161/01.cir.85.4.1491

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

Review 1.  Blockade of cardiac potassium and other channels by antihistamines.

Authors:  E Delpón; C Valenzuela; J Tamargo
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

Review 2.  The risk of cardiac events and genotype-based management of LQTS patients.

Authors:  Grazyna Markiewicz-Łoskot; Ewa Moric-Janiszewska; Urszula Mazurek
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

Review 3.  Electrophysiologic effects of potassium channel openers.

Authors:  W Haverkamp; M Borggrefe; G Breithardt
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

4.  Biomarkers and endogenous determinants of dofetilide-induced torsades de pointes in α(1) -adrenoceptor-stimulated, anaesthetized rabbits.

Authors:  Attila S Farkas; László Rudas; Péter Makra; Norbert Csík; István Leprán; Tamás Forster; Miklós Csanády; Julius Gy Papp; András Varró; András Farkas
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

5.  Effects of cromakalim or glibenclamide on arrhythmias and dispersion of refractoriness in chronically infarcted in anesthetized dogs.

Authors:  A J D'Alonzo; J C Sewter; R B Darbenzio; T A Hess
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

6.  Pro- and antiarrhythmic effects of ATP-sensitive potassium current activation on reentry during early afterdepolarization-mediated arrhythmias.

Authors:  Marvin G Chang; Enno de Lange; Guillaume Calmettes; Alan Garfinkel; Zhilin Qu; James N Weiss
Journal:  Heart Rhythm       Date:  2012-12-12       Impact factor: 6.343

7.  Cytosolic Ca2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome.

Authors:  Bum-Rak Choi; Francis Burton; Guy Salama
Journal:  J Physiol       Date:  2002-09-01       Impact factor: 5.182

8.  Long QT syndrome: A therapeutic challenge.

Authors:  Maully Shah; Christopher Carter
Journal:  Ann Pediatr Cardiol       Date:  2008-01

9.  Noninvasive cardiac activation imaging of ventricular arrhythmias during drug-induced QT prolongation in the rabbit heart.

Authors:  Chengzong Han; Steven M Pogwizd; Cheryl R Killingsworth; Zhaoye Zhou; Bin He
Journal:  Heart Rhythm       Date:  2013-06-14       Impact factor: 6.343

Review 10.  Modulation of ischemia by regulation of the ATP-sensitive potassium channel.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.